Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
Associated Press - Wednesday November 21, 2001
Linda A. Johnson, Associated Press Writer HFR
A four-year study of 1,028 HIV-infected children and teen-agers found that combining protease inhibitors with standard AIDS drugs cut the risk of death by two-thirds, to less than 1 percent annually. Some children improved dramatically.
"The children are acting as if they didn't have AIDS," said study leader Dr. James M. Oleske, director of pediatric infectious diseases at University of Medicine and Dentistry of New Jersey in Newark. "They started growing, they started gaining weight, they started enjoying life. They didn't develop infections as much."
Since 1996, most adult AIDS patients have taken cocktails consisting of protease inhibitors along with older medicines. The combination has greatly suppressed the virus and cut deaths. For many patients, AIDS - once regarded as a death sentence - has been reduced to a chronic disease.
Because of protease inhibitors and other advances, some children infected with the AIDS virus around the time of birth are now in college; doctors once worried they would not live to finish grammar school.
Until recently, however, many doctors were not sure if children would get the same benefit from protease inhibitors as adults do. Some doctors hesitated to prescribe the drugs because of side effects such as bone loss.
The latest study looked at children treated for HIV at 40 pediatric AIDS clinics around the country. Their doctors and their parents decided on the course of treatment for each child.
The findings were reported in Thursday's New England Journal of Medicine. In 1996, when doctors had to guess at children's doses of protease inhibitors and there were no liquid forms for the very young, only 7 percent in the study were taking them along with standard AIDS drugs. Those problems were soon solved, and by 1999, 73 percent of the children in the study were taking protease inhibitors.
Meanwhile, the annual death rate of study participants dropped from 5.3 percent to 0.7 percent.
"This is a great study," said Dr. Sharon Nachman, director of the Maternal Child HIV Center at the State University of New York at Stony Brook. "It shows we've moved from a fatal disease to a chronic illness that can be treated."
- On the Net: http://www.nejm.com Pediatric AIDS Clinical Trials Group: http://pactg.s-3.com
011121
AP011128
Copyright © 2001 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, Pacific Life Foundation, and donations from users like you.
Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .